Protalix BioTherapeutics Dismisses Stockholder Class Action

SEC Filing 8-K (0001558370-25-009989)

On August 1, 2025, Protalix BioTherapeutics, Inc. announced the dismissal of a stockholder class action lawsuit filed by Kevin Mathew Thomas. The lawsuit, filed on March 10, 2025, alleged that certain provisions in the company's Amended and Restated Bylaws violated Delaware law. The company and its Board of Directors denied all allegations of wrongdoing. On May 8, 2025, the Board amended the Bylaws, leading the plaintiff to agree that his claims were moot. The company agreed to pay $160,000 in fees and expenses to the plaintiff's counsel. On July 23, 2025, the Court entered a Stipulation and Order dismissing the case with prejudice. The Court did not rule on the amount of fees and expenses.